CL2011001453A1 - Metodo para identificar un anticuerpo o fragmento del mismo de union a antigeno expresado en una celula, particulamente una celula b, que se une especificamente a un antigeno de interes de la superficie celular. - Google Patents

Metodo para identificar un anticuerpo o fragmento del mismo de union a antigeno expresado en una celula, particulamente una celula b, que se une especificamente a un antigeno de interes de la superficie celular.

Info

Publication number
CL2011001453A1
CL2011001453A1 CL2011001453A CL2011001453A CL2011001453A1 CL 2011001453 A1 CL2011001453 A1 CL 2011001453A1 CL 2011001453 A CL2011001453 A CL 2011001453A CL 2011001453 A CL2011001453 A CL 2011001453A CL 2011001453 A1 CL2011001453 A1 CL 2011001453A1
Authority
CL
Chile
Prior art keywords
antigen
cell
antibody
cells
interest
Prior art date
Application number
CL2011001453A
Other languages
English (en)
Inventor
Valerie Hulmann-Cottier
David Urech
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CH2009/000219 external-priority patent/WO2009155723A2/en
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of CL2011001453A1 publication Critical patent/CL2011001453A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

UN MÉTODO PARA IDENTIFICAR UN ANTICUERPO O FRAGMENTO DE UNIÓN A AMTÍGENO DEL MISMO QUE SE UNE<br /> ESPECÍFICAMENTE A UN ANTÍGENO DE INTERÉS DE LA SUPERFICIECELULAR, QUE COMPRENDE:<br /> (A) PROPORCIONAR UNA PLURALIDAD DE CÉLULAS QUE EXPRESAN EL ANTICUERPO ENLAZADAS<br /> OPERATIVAMENTE A UN PRIMER MARCADOR CLASIFICABLE;<br /> (B) PROPORCIONAR UNA PLURALIDAD DE CÉLULAS QUE EXPRESAN EL ANTÍGENO ENLAZADAS<br /> OPERATIVAMENTE A UN SEGUNDO MARCADOR CLASIFICABLE, DONDE EL ANTÍGENO DE INTERÉS ES EXHIBIDO EN LA SUPERFICIE<br /> DE LA CÉLULA QUE EXPRESA EL ANTÍGENO;<br /> (C) PONER EN CONTACTO LAS CÉLULAS QUE EXPRESAN EL ANTÍGENO CON LAS CÉLULAS QUE EXPRESAN<br /> EL ANTICUERPO; Y<br /> (D) SEPARAR DE LA PLURALIDAD DE CÉLULAS QUE EXPRESAN EL ANTICUERPO, UNA O MÁS CÉLULAS<br /> QUE EXPRESAN EL ANTICUERPO QUE PUEDEN UNIRSE ESPECÍFICAMENTE A LAS CÉLULAS QUE EXPRESAN EL ANTÍGENO<br /> USANDO UN CLASIFICADOR DE CÉLULAS, DONDE LA PRESENCIA DE LOS MARCADORES CLASIFICABLES PRIMERO Y SEGUNDO EN<br /> UN COMPLEJO CELULAR ÚNICO ES INDICADORA DE LA UNIÓN DE UNA CÉLULA QUE EXPRESA EL ANTICUERPO A UNA CÉLULA QUE<br /> EXPRESA EL ANTÍGENO, IDENTIFICANDO ASÍ UN ANTICUERPO QUE SE UNE A UN ANTÍGENO DE INTERÉS.
CL2011001453A 2009-02-24 2011-06-15 Metodo para identificar un anticuerpo o fragmento del mismo de union a antigeno expresado en una celula, particulamente una celula b, que se une especificamente a un antigeno de interes de la superficie celular. CL2011001453A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15510509P 2009-02-24 2009-02-24
US15504109P 2009-02-24 2009-02-24
CH8322009 2009-06-02
PCT/CH2009/000219 WO2009155723A2 (en) 2008-06-25 2009-06-25 STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Publications (1)

Publication Number Publication Date
CL2011001453A1 true CL2011001453A1 (es) 2012-02-24

Family

ID=48917567

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001453A CL2011001453A1 (es) 2009-02-24 2011-06-15 Metodo para identificar un anticuerpo o fragmento del mismo de union a antigeno expresado en una celula, particulamente una celula b, que se une especificamente a un antigeno de interes de la superficie celular.

Country Status (12)

Country Link
JP (3) JP6161655B2 (es)
KR (4) KR101689791B1 (es)
CN (1) CN105116138A (es)
BR (1) BRPI1005398A2 (es)
CL (1) CL2011001453A1 (es)
ES (1) ES2618181T3 (es)
IL (4) IL226955A (es)
MX (1) MX352922B (es)
PH (1) PH12014502468B1 (es)
RU (2) RU2577965C2 (es)
SG (3) SG10201708233VA (es)
ZA (1) ZA201103125B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016462B (zh) * 2019-02-20 2020-04-24 优睿赛思(武汉)生物科技有限公司 从脾脏细胞中高效分离单个抗原特异性b淋巴细胞的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63253098A (ja) * 1987-04-10 1988-10-20 Ube Ind Ltd ヒト抗体に対するモノクロ−ナル抗体、その製法及び用途
IL91948A (en) 1988-10-26 1994-05-30 Immunomedics Removal of immunoreactive components from a sample
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
KR0119909B1 (ko) * 1993-10-05 1997-10-20 김은영 플로우 사이토미터를 이용한 고상형 면역 측정방법
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2267620A1 (en) * 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
CN102093477B (zh) * 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1396182A (zh) * 2002-07-31 2003-02-12 陕西超英生物医学研究开发有限公司 人内皮生长因子受体2蛋白全人单克隆抗体及其制备方法
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
EP1561107A1 (en) * 2002-11-13 2005-08-10 Micromet AG Method for identifying antigen specific b cells
JP4336812B2 (ja) * 2003-03-07 2009-09-30 博夫 岩田 細胞に発現する表面抗原を迅速に同定するための分析方法
EP1623229A2 (en) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
EP2343363A1 (en) * 2005-07-01 2011-07-13 John Schrader Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining
US20070134249A1 (en) 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
AU2006334029B2 (en) * 2005-12-28 2013-01-31 Osaka University An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008004834A1 (en) * 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor

Also Published As

Publication number Publication date
RU2017135831A (ru) 2019-04-09
RU2017135831A3 (es) 2019-04-09
RU2577965C2 (ru) 2016-03-20
SG2014014864A (en) 2014-09-26
IL226956A0 (en) 2013-07-31
IL263158B (en) 2019-10-31
PH12014502468A1 (en) 2016-01-18
RU2011124039A (ru) 2012-12-20
JP2017192384A (ja) 2017-10-26
KR20180005752A (ko) 2018-01-16
KR20190020202A (ko) 2019-02-27
JP6604989B2 (ja) 2019-11-13
BRPI1005398A2 (pt) 2019-03-26
KR102059866B1 (ko) 2019-12-27
IL226956A (en) 2015-04-30
JP2015146825A (ja) 2015-08-20
KR20160022397A (ko) 2016-02-29
IL226955A0 (en) 2013-07-31
KR101689791B1 (ko) 2016-12-26
SG10201708233VA (en) 2017-11-29
KR20160150642A (ko) 2016-12-30
MX352922B (es) 2017-12-14
IL263158A (en) 2018-12-31
CN105116138A (zh) 2015-12-02
JP2018196395A (ja) 2018-12-13
ES2618181T3 (es) 2017-06-21
SG10201408247SA (en) 2015-02-27
ZA201103125B (en) 2012-08-29
PH12014502468B1 (en) 2016-01-18
IL226955A (en) 2015-04-30
KR101817279B1 (ko) 2018-01-10
JP6161655B2 (ja) 2017-07-12
IL237985B (en) 2018-12-31

Similar Documents

Publication Publication Date Title
CL2012003375A1 (es) Anticuerpo monoclonal que se une a enzima ariloxialcanoato dioxigenasa (aad-12); linea celular de hibridomas que produce dicho anticuerpo; metodos para detectar la presencia de la enzima aad-12; metodo para la deteccion cuantitativa de una enzima aad-12.
AR118118A2 (es) Anticuerpos bivalentes biespecíficos
CO2017006651A2 (es) Anticuerpos anti-c5
CL2008002085A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
CL2008001175A1 (es) Metodo para distinguir semillas que contienen un elemento genetico de interes a partir de una muestra de un lote,basado en la presencia de una proteina marcadora fluorescente roja.
AR092968A1 (es) Anticuerpos monoclonales y metodos de deteccion para enzimas que confieren resistencia a la fosfinotricina-n-acetil-transferasa
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
AR093984A1 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
AR091116A1 (es) Anticuerpos biespecificos y sus metodos de uso
MX2017015011A (es) Ensayo a base de celulas para detectar homodimeros anti-cd3.
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
CR20120371A (es) Antagonistas de pcsk9
EP4249605A3 (en) Methods for analyte detection
PE20190229A1 (es) Anticuerpos anti-fcrn
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
TR201901668T4 (tr) Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
CL2012000822A1 (es) Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; metodo para reducir nivel de proteina viral.
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
CL2009002004A1 (es) Anticuerpo o fragmento del mismo que se une al receptor de interleuquina 4 que comprende una region variable de cadena liviana y pesada; secuencias de acido nucleico que codifica dichas regiones; vector que comprende dicha secuencia; celula huesped; metodo para producir dicho anticuerpo; y uso de dicho anticuerpo para trastornos inmunologicos.
CL2011002611A1 (es) Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
BR112013011167A2 (pt) &#34;exame de suplementos eficientes e efetivos para o desenvolvimento de meio quimicamente definido em cultura de células.&#34;
CL2012001403A1 (es) Anticuerpo que une tat211; célula que la produce; acido nucleico que la codifica; metodo para identificar un primer anticuerpo que se une con un epitope antigenico tat211 unido por un segundo anticuerpo; metodo para inhibir el crecimiento de una celula que expresa un polipeptido tat211